Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Anderson

Urology Charlottesville, VA Medical Doctor

NPI 1922156181 CMS profile 1015997

500 Martha Jefferson Dr, Charlottesville, VA 22911

Open in the dashboard

General payments

$9,465

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Anderson of Charlottesville, VA is reported in the CMS Open Payments database as having received $9,465 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $207 3
2024 General $423 8
2023 General $1,489 11
2022 General $1,935 44
2021 General $4,763 48
2020 General $322 15
2019 General $326 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Anderson
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Mark Anderson were reported at $207. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Mark Anderson Urology median Middle half National median
2019 $326 $480 $147–$1,201 $163
2020 $322 $246 $87–$645 $114
2021 $4,763 $358 $111–$1,000 $132
2022 $1,935 $476 $143–$1,263 $149
2023 $1,489 $560 $168–$1,461 $160
2024 $423 $563 $170–$1,464 $164
2025 $207 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $3,047 3 payments
  2. PROCEPT BioRobotics Corporation $2,333 15 payments
  3. Teleflex LLC $1,289 15 payments
  4. Olympus America Inc. $449 8 payments
  5. Astellas Pharma US Inc $426 23 payments
  6. Dendreon Pharmaceuticals LLC $290 12 payments
  7. Pfizer Inc. $184 10 payments
  8. Agiliti Surgical, Inc. $184 2 payments
  9. Janssen Biotech, Inc. $152 5 payments
  10. Urovant Sciences Inc $146 6 payments
  11. Other $964 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,745 131 payments
  2. Debt forgiveness $3,000 1 payment
  3. Travel and Lodging $2,572 11 payments
  4. Education $148 3 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,000 1 payment
  2. AQUABEAM ROBOTIC SYSTEM $2,124 11 payments
  3. UroLift System $1,046 10 payments
  4. XTANDI $351 20 payments
  5. PROVENGE $290 12 payments
  6. UROLIFT $242 5 payments
  7. CYSTO-NEPHRO VIDEOSCOPE $233 2 payments
  8. MYRBETRIQ $223 13 payments
  9. iTIND System $201 4 payments
  10. AQUABEAM SYSTEM $186 3 payments
  11. Other $2,101 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

612

Median for Urology: 1,053

Drug cost

$14,052

Median for Urology: $101,464

Branded share of claims

15%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Solifenacin Succinate Generic 125 $7,891
Potassium Citrate Er Potassium Citrate Brand 13 $1,440
Trospium Chloride Generic 16 $1,170
Finasteride Generic 94 $1,049
Tamsulosin Hcl Generic 98 $1,039
Oxybutynin Chloride Generic 74 $287
Cefdinir Generic 29 $265
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 17 $224
Cephalexin Generic 18 $194
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 14 $146

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$146,600

Medicare's payments for the services billed

Medicare patients

345

Average age 76

Services billed

1,590

100 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 33%
Ischemic heart disease 31%
Chronic kidney disease 30%
Depression 27%
Cancer 23%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record